Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Current Clinical Trials in the Northwest

Spring 2002

Primary Infection Clinic
Treatment and observational studies of newly acquired HIV infection (within the prior 8 months). Treatment options are abacavir, lamivudine, efavirenz OR abacavir, lamivudine, indinavir/ritonavir. Contact either Claire or Janine @ 206-720-4340.

Detection of HIV in HSV Lesions
The study follows subjects through two genital herpes [HSV-2] recurrences to determine if valacyclovir reduces detectable HIV in herpes lesions. Participants must have recognized recurrent genital HSV-2 and not be on chronic suppressive HSV therapy. $125 per recurrence. Contact Steve @ 206-720-4340.

Gay Couples HHV-8 Study
Two-year study of the Kaposi's sarcoma herpes virus to characterize the role of oral transmission and to determine if a primary infection syndrome exists. Participants can be HIV-positive or HIV-negative and should be in a steady relationship. $100 per study participant with free testing/counseling. Contact Steve @ 206-720-4340.

ACTG 5030
Preventing cytomegalovirus (CMV) organ damage with valganciclovir. Main eligibility includes having antibodies to CMV, a CD4 below 100, and a viral load above 400. Payment for some clinic visits. Contact Alyssa or Lori @ 206-731-3184.

Advertisement
ACTG 5068
Structured treatment interruption (STI) and a vaccine. Subjects will receive antiretroviral drugs with STI, and either the ALVAC-HIV vCP1452 (canarypox) vaccine or a vaccine placebo. Requires person on first anti-HIV combination (unless switched because of side effects), and no prior use of abacavir or recent use of hydroxyurea. Payment for participation in sub-studies (men only). Contact Alyssa or Lori @ 206-731-3184.

ACTG 5078
Carotid artery thickness. Ultrasound tests measure artery thickness in HIV-negative and HIV-positive participants. $25 paid for each ultrasound test. Contact Alyssa or Lori @ 206-731-3184.

ACTG 5082
Treatment to lower blood insulin and body fat. Subjects are assigned to combinations of Metformin, Rosiglitazone, and/or placebos. Participants will be HIV-positive men and women aged 18-65 with increased body fat, viral loads above 10,000, on stable antiretroviral therapy, on stable hormone therapy or off for at least 6 months, with no prior use of anti-diabetic medications. $25 will be paid for each CT or DEXA scan. Contact Alyssa or Lori @ 206-731-3184.

ACTG 5090
Treatment of HIV-associated dementia. Selegiline transdermal system (STS patch) vs. patch placebo. All patients receive STS patch during 2nd half of study. Main eligibility is documented HIV dementia and on anti-HIV drugs for at least 8 weeks. $20 - $100 paid for some tests. Contact Alyssa or Lori @ 206-731-3184.

ACTG 5092
Treatment of HCV/HIV co-infection. Subjects are given a combination of Ribavirin and AZT or d4T. Participants must be HIV-positive and HCV-positive, at least 13 years old, with CD4 above 100, on AZT or d4T at least 4 weeks prior to entry and planning to start Ribavirin. This 8-week study pays $75 for each of two 10-hour visits. Contact Alyssa or Lori @ 206-731-3184.

ACTG 5095
Initial treatment with a PI-sparing regimen. Subjects are randomly assigned to various combinations with ABC, 3TC, ZDV, EFV, and/or placebos. No prior antiretroviral treatment. Payment for some sub-studies. Contact Alyssa or Lori @ 206-731-3184.

ACTG 5117
Observational study of peripheral neuropathy. Subjects are HIV-positive males and non-pregnant females at least 13 years old who have been on antiretroviral therapy at least 15 consecutive weeks in the past, have CD4 count below 300, no history of spinal surgery, no untreated diabetes mellitus, and no history of diabetic neuropathy. Four visits over a 1-year period lasting 1 to 3 hours each. Participants will be paid $125 for visits 2 and 4, $100 for visit 3. Contact Alyssa or Lori @ 206-731-3184.

ACTU 132
Effect of anti-HIV drugs on brain function and HIV in spinal fluid. Study involves one or more lumbar punctures (spinal taps), and subjects will be paid $100 to $150 for each. Contact Margot @ 206-731-3184.

HIV and Garlic Trial
Clinical study on the potential of garlic to lower high blood cholesterol. Must be on successful HAART for at least 6 months, with cholesterol above 200, triglycerides below 500. Compensation: $200 upon study completion. Contact Deana Rich @ 425-602-3171.

CRC 0142 GSK-21
Anti-HIV therapy for people who have never taken HIV drugs. Abacavir OR AZT combined with 3TC and Sustiva. Must have viral load of 400 copies or higher, more than 50 T-helper cells. Study-related lab tests and physical exams are free. Contact Janice @ 206-386-2523.

CRC 0122 CRX
Anti-HIV therapy for patients with a failed a regimen containing Sustiva, Viramune or Delavirdine. Subjects will receive Crixivan and Norvir twice a day OR Viracept twice daily. Two other HIV drugs of the patient's/provider's choice will also be prescribed. Participants must have viral load of 2,000 copies or higher, more than 50 T-helper cells, never taken a protease inhibitor. Genotyping and phenotying will be performed. Study-related lab tests and physical exams are free. Contact Janice @ 206-386-2523.

HPTU 032 Gel Study
Study testing the safety of two different microbicidal gels compared to an over-the-counter lube people use during sex. Participants will be HIV-positive men. $25 at each visit. Contact Jeffery or Paul @ 206-521-5821.

HVTU -- Multiple Exposures Study
Eligible participants are HIV-negative men or women repeatedly exposed to HIV by an HIV-positive partner. We are looking for BOTH partners. Participants are compensated for their time. Contact Jeffery or Paul @ 206-667-2300.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Perspective.
 
See Also
Washington

Tools
 

Advertisement